Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of HL-TOF vs Xeljanz in Healthy Volunteers
NCT04114461Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tofacitinib in rheumatoid arthritis (RA) (2 arms), sponsored by Hanlim Pharm. Primary endpoints: Maximum Plasma Concentration at 12 hour and Area Under the Curve at 12 hour. Started Nov 2019; status: completed.
02
Drugs
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04114461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04114461.